Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;48(3):334-342.
doi: 10.1111/ceo.13713. Epub 2020 Jan 30.

Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy

Esteban A Gonzalez  1   2 , Fernanda Visioli  3 , Gabriela Pasqualim  1   2 , Carolina F M de Souza  4 , Diane R Marinho  5   6 , Roberto Giugliani  1   2   4 , Ursula Matte  1   2 , Guilherme Baldo  1   2
Affiliations

Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy

Esteban A Gonzalez et al. Clin Exp Ophthalmol. 2020 Apr.

Abstract

Background: Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by α-L-iduronidase deficiency, resulting in accumulation of glycosaminoglycans (GAG). Ophthalmological manifestations are common in MPS I patients and often lead to visual impairment. Accumulation of GAG in corneal or retinal tissues reduces vision causing corneal opacity and neurosensory complications. One available treatment for MPS I patients is enzyme replacement therapy (ERT), but the results of such treatment on eye disease are still debatable. Therefore, we aimed to determine the progression of ocular manifestations as well as the effectiveness of intravenous ERT in MPS I.

Methods: Corneal and retinal analyses were perform in eyes from 2- to 8-month normal and MPS I mice. Some MPS I mice received ERT (1.2 mg/kg of laronidase) every 2 weeks from 6 to 8 months and histological findings were compared with controls. Additionally, cornea from two MPS I patients under ERT were evaluated.

Results: Mouse corneal tissues had GAG accumulation early in life. In the retina, we found a progressive loss of photoreceptor cells, starting at 6 months. ERT did not improve or stabilize the histological abnormalities. MPS I patients, despite being on ERT for over a decade, presented GAG accumulation in the cornea, corneal thickening, visual loss and needed corneal transplantation.

Conclusion: We provide data on the time course of ocular alteration in MPS I mice. Our results also suggest that ERT is not effective in treating the progressive ocular manifestations in MPS I mice and fails to prevent corneal abnormalities in patients.

Keywords: Scheie, Hurler and Hurler-Scheie syndrome; corneal opacity; enzyme replacement therapy; mucopolysaccharidosis type I; retinal abnormality.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol. 2006;51(1):1-17.
    1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Co; 2001:3421-3454.
    1. Pastores GM, Arn P, Beck M, et al. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab. 2007;91(1):37-47.
    1. Giugliani R, Federhen A, Rojas MVM, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33(4):589-604.
    1. Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye (Lond). 2006;20(5):553-563.

Publication types

LinkOut - more resources